Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT01775514
  4. Details
NCT01775514 Clinical Trial

A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics

Cancer Clinical Trial

Official title:
Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish "Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma" Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01775514
Other study ID # ML28579
Secondary ID
Status Completed
Phase N/A
First received January 18, 2013
Last updated November 1, 2016
Start date October 2012
Est. completion date October 2015

Study information
Verified date November 2016
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority Turkey: Ministry of Health
Study type Observational

Clinical Trial Summary

This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.

Recruitment information / eligibility
Status Completed
Enrollment 32277
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma

- Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer

Exclusion Criteria:

- Participants not living in the city or representative region of the study center

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Turkey, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months No
Primary Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region 36 months No
Primary Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months No
Primary Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months No
Primary Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region 36 months No
Secondary Percentage of Participants Categorized by Tumor Size 36 months No
Secondary Percentage of Participants Categorized by Histopathology Diagnosis 36 months No
Secondary Percentage of Participants Categorized by the Staging System 36 months No
Secondary Percentage of Participants Categorized by Surgery Type 36 months No
Secondary Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments) 36 months No
Secondary Percentage of Participants With Metastasis Categorized by Treatment Regimens Used (ie, First-line, Second-line, Third-line, or Forth-line Chemotherapy) 36 months No
Secondary Overall Survival (OS) 36 months No
Secondary Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 36 months No
Secondary Percentage of Participants With Family History of Cancer and Other Conditions 36 months No
Secondary Percentage of Participants With History of Another Primary Cancer 36 months No
Secondary Percentage of Participants Categorized by Diagnostic Methods 36 months No
Secondary Percentage of Participants With Metastasis 36 months No
Secondary Percentage of Participants Categorized by Tumor Localization 36 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients